entertainment -WSS

entertainment

author：leisure time 2025-10-03 19:57:08 - browse：74

Former MIT and Whitehead Institute star biologist David Sabatini, who lost his positions after he was accused of violating sexual harassment policies in 2021, is resuming his science career, taking a post at a Czech research institute in Prague.

Sabatini, of Cambridge, confirmed in a phone call from Prague that he has accepted a position as a “senior group leader” at the Institute of Organic Chemistry and Biochemistry, known as IOCB Prague. Sabatini said he will be recruiting staff and running a laboratory in the Czech Republic capital to investigate scientific questions in the areas of cell growth and metabolism, similar to his past research in Cambridge.

“I’m very grateful to be given the opportunity to do science again,” said Sabatini, who began working at the institute last month.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： An inside look at PIPEs, biotech's buzzy new financing tool

leisure time

knowledge

WSS

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Finland to offer bird flu vaccine to select groups of people, a possible global first

Medicare Advantage's lean provider networks lead CMS complaints

FDA does about

Finland to offer bird flu vaccine to select groups of people, a possible global first

ALS groups 'won't be played again' by the FDA, drug sponsors

hotspot

entertainment

Wikipedia

23andMe had bad news about my health. I wish a person had delivered it

Illumina board agrees to spin off Grail, as divestment plans proceed

23andMe had bad news about my health. I wish a person had delivered it

Data don't support strong claims for Covid

As demand for Covid shots wanes, Moderna seeks its next success

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Heart attack and stroke risk calculators need revising

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Psychedelics group wrestles with new pharma identity

Eli Lilly’s Zepbound improved liver scarring in mid

hotspot

Change Healthcare cyberattack outage could last weeks

FogPharma raises $145 million in rare Series E round

International team creates first chimeric human

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Covid isolation guidance eased by the CDC

Medicare Advantage's lean provider networks lead CMS complaints

Wikipedia

leisure time

knowledge

entertainment